Biren Amin
Stock Analyst at Piper Sandler
(3.49)
# 1,165
Out of 4,479 analysts
27
Total ratings
53.33%
Success rate
4.22%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $205 | $154.20 | +32.94% | 3 | Jul 1, 2024 | |
| CRGX CARGO Therapeutics | Initiates: Overweight | $37 | $15.83 | +133.73% | 1 | Jun 27, 2024 | |
| SLDB Solid Biosciences | Reiterates: Overweight | $20 | $5.96 | +235.57% | 1 | Jun 21, 2024 | |
| IMNM Immunome | Initiates: Overweight | $27 | $11.70 | +130.77% | 1 | May 31, 2024 | |
| ELEV Elevation Oncology | Initiates: Overweight | $10 | $2.80 | +257.14% | 1 | May 31, 2024 | |
| APLS Apellis Pharmaceuticals | Initiates: Neutral | $46 | $34.98 | +31.50% | 1 | May 31, 2024 | |
| ALLO Allogene Therapeutics | Initiates: Overweight | $11 | $2.16 | +409.26% | 1 | May 31, 2024 | |
| ACLX Arcellx | Initiates: Overweight | $70 | $53.25 | +31.46% | 1 | May 31, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $120 → $70 | $3.57 | +1,860.78% | 2 | May 19, 2023 | |
| BCAB BioAtla | Initiates: Buy | n/a | $1.32 | - | 1 | Jan 11, 2021 | |
| ALDX Aldeyra Therapeutics | Initiates: Buy | n/a | $3.25 | - | 1 | Oct 30, 2020 | |
| TSHA Taysha Gene Therapies | Initiates: Buy | n/a | $2.16 | - | 1 | Oct 19, 2020 | |
| KALA Kala Pharmaceuticals | Downgrades: Hold | n/a | $6.71 | - | 1 | Sep 14, 2020 | |
| IMTX Immatics | Initiates: Buy | n/a | $12.02 | - | 1 | Jul 24, 2020 | |
| CTMX CytomX Therapeutics | Downgrades: Hold | n/a | $1.32 | - | 1 | Jun 1, 2020 | |
| CALA Calithera Biosciences | Initiates: Buy | n/a | $0.01 | - | 1 | Mar 27, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | n/a | $1,044.66 | - | 1 | Feb 25, 2020 | |
| ADXS Ayala Pharmaceuticals | Downgrades: Hold | n/a | $0.28 | - | 1 | Jun 13, 2018 | |
| BLUE bluebird bio | Upgrades: Buy | n/a | $0.92 | - | 2 | Dec 11, 2017 | |
| ANAB AnaptysBio | Initiates: Buy | n/a | $23.94 | - | 1 | Nov 9, 2017 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | n/a | $137.49 | - | 1 | Oct 3, 2017 | |
| VRTX Vertex Pharmaceuticals | Initiates: Buy | n/a | $473.78 | - | 1 | Jul 11, 2017 | |
| NERV Minerva Neurosciences | Initiates: Buy | n/a | $3.08 | - | 1 | Mar 6, 2017 |
Sarepta Therapeutics
Jul 1, 2024
Maintains: Overweight
Price Target: $205
Current: $154.20
Upside: +32.94%
CARGO Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: $37
Current: $15.83
Upside: +133.73%
Solid Biosciences
Jun 21, 2024
Reiterates: Overweight
Price Target: $20
Current: $5.96
Upside: +235.57%
Immunome
May 31, 2024
Initiates: Overweight
Price Target: $27
Current: $11.70
Upside: +130.77%
Elevation Oncology
May 31, 2024
Initiates: Overweight
Price Target: $10
Current: $2.80
Upside: +257.14%
Apellis Pharmaceuticals
May 31, 2024
Initiates: Neutral
Price Target: $46
Current: $34.98
Upside: +31.50%
Allogene Therapeutics
May 31, 2024
Initiates: Overweight
Price Target: $11
Current: $2.16
Upside: +409.26%
Arcellx
May 31, 2024
Initiates: Overweight
Price Target: $70
Current: $53.25
Upside: +31.46%
Zentalis Pharmaceuticals
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $3.57
Upside: +1,860.78%
BioAtla
Jan 11, 2021
Initiates: Buy
Price Target: n/a
Current: $1.32
Upside: -
Aldeyra Therapeutics
Oct 30, 2020
Initiates: Buy
Price Target: n/a
Current: $3.25
Upside: -
Taysha Gene Therapies
Oct 19, 2020
Initiates: Buy
Price Target: n/a
Current: $2.16
Upside: -
Kala Pharmaceuticals
Sep 14, 2020
Downgrades: Hold
Price Target: n/a
Current: $6.71
Upside: -
Immatics
Jul 24, 2020
Initiates: Buy
Price Target: n/a
Current: $12.02
Upside: -
CytomX Therapeutics
Jun 1, 2020
Downgrades: Hold
Price Target: n/a
Current: $1.32
Upside: -
Calithera Biosciences
Mar 27, 2020
Initiates: Buy
Price Target: n/a
Current: $0.01
Upside: -
Regeneron Pharmaceuticals
Feb 25, 2020
Upgrades: Buy
Price Target: n/a
Current: $1,044.66
Upside: -
Ayala Pharmaceuticals
Jun 13, 2018
Downgrades: Hold
Price Target: n/a
Current: $0.28
Upside: -
bluebird bio
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.92
Upside: -
AnaptysBio
Nov 9, 2017
Initiates: Buy
Price Target: n/a
Current: $23.94
Upside: -
Neurocrine Biosciences
Oct 3, 2017
Maintains: Buy
Price Target: n/a
Current: $137.49
Upside: -
Vertex Pharmaceuticals
Jul 11, 2017
Initiates: Buy
Price Target: n/a
Current: $473.78
Upside: -
Minerva Neurosciences
Mar 6, 2017
Initiates: Buy
Price Target: n/a
Current: $3.08
Upside: -